Krystal Biotech
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Krystal Biotech (KRYS) | 9.15B | 41.97 | 6.38 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 4.6% above Morningstar's fair value estimate.
Fair value
Krystal Biotech Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 3% premium over our quantitative fair value estimate of $294.79 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The firm's unfavorable dividend structure decreases our valuation estimate. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. Reflecting the firm's dividends is its forward dividend yield of 0%, which sits in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are overvalued.
The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's cash flow yield of 3.1%, a core component of profitability, falls in the bottom 40% compared with peers globally. At the current valuation, the yield of cash flow from operations to investors looks paltry. This characteristic further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Krystal Biotech discussion 0 comments